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Now Is the Time to Focus on Health Care Delivery*Sean P. Pinney, MDO ver the past 3 decades, heart failure patientshave enjoyed major improvements in sur-vival and quality of life. Well-conducted
clinical trials have proven the effectiveness of
neurohormonal antagonists, cardiac resynchroniza-
tion therapy (CRT), and implantable cardioverter-
deﬁbrillators (ICDs), and their widespread use in
eligible patients with heart failure with reduced ejec-
tion fraction (HFrEF) has been endorsed by the most
recent clinical guidelines (1). Nonetheless, signiﬁcant
gaps in quality of care continue to exist in contempo-
rary practice, including disparities by sex, socioeco-
nomic class, and race/ethnicity.
For years, it has been recognized that African-
Americans are less likely than whites to receive
intensive cardiac procedures such as percutaneous
coronary intervention, coronary artery bypass graft-
ing, ICD therapy, and heart transplantation. Further-
more, the diffusion of innovative technologies from
clinical trials into practice seems to occur at a slower
rate for minorities. Even after adjusting for poten-
tially confounding factors, such as disease severity
and access to care, these disparities in care continue
to persist and likely contribute to adverse clinical
outcomes (2). Although 1 recent study promisingly
suggested that the racial/ethnic gap in CRT use is
narrowing, the troubling fact remains that unex-
plained differences in care remain in contemporary
practice (3).
No single factor can account for the variances in
care. Rather, several mechanisms have been offered as*Editorials published in the Journal of the American College of Cardiology
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fees and honoraria from CareDx and Thoratec, Inc.potential explanations. These include patient-speciﬁc
forces such as poor health literacy; ﬁnancial, cultural,
or social barriers preventing access to care; and lack of
engagement or distrust of the medical system. There
may be system-level challenges that limit easy access
to quality health care facilities, like those faced by
rural populations. Some communities may be served
by a health care system with limited ﬁnancial re-
sources. Such hospitals may lack the necessary
equipment or resources to deliver advanced cardiac
care or may be unable to recruit and retain quality
health care providers. There also may be provider-
speciﬁc forces that directly impact care delivery,
such as level of training, experience, cultural insen-
sitivity, or bias.
One additional rationale has been offered to
explain the lower rate of delivering cardiac resynch-
ronization deﬁbrillator (CRT-D) therapy to eligible
women and minorities: their under-representation in
clinical trials creates uncertainty as to whether the
overall positive study results are applicable to these
subgroups. This is a hollow argument that contradicts
a widely-held tenet of clinical trials, namely that such
qualitative subgroup interactions are in fact quite
uncommon (4). Most therapies that are effective in a
population with a diagnosis are effective in most
members of that population. When considered in the
context of HFrEF, the clinical implication is that this
therapy should be extended to all patients with an
ejection fraction <35% and prolongation of the QRS
interval beyond 150 ms. Before deciding to withhold
such therapy in women or any racial/ethnic subgroup,
the provider must ﬁrst prove that a lack of beneﬁt or
harm exists in those groups. The burden of proof in
this case is quite high.SEE PAGE 797In this issue of the Journal, Ziaeian et al. (5)
address this question head on by conducting a
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809pre-speciﬁed analysis of IMPROVE-HF (Registry to
Improve the Use of Evidence-Based Heart Failure
Therapies in the Outpatient Setting), which was
originally designed to evaluate a practice-speciﬁc
performance improvement initiative to increase
adherence to guideline-directed HFrEF therapies.
Ziaeian et al. (5) examined the clinical effectiveness
of CRT or ICD therapy as a function of race/ethnicity.
Data from this 15,000-patient registry offer a unique
opportunity to explore outcomes in real-world clin-
ical practice. In this particular analysis, the use of
CRT or ICD therapy at study enrollment was associated
with a profound 36% reduction in 24-month mortality
and was of a similar magnitude in white, black,
and other minority subgroups (5). Using multivariate
Generalized Estimating Equations modeling, these
investigators showed that there was no subgroup–
treatment effect interaction, supporting the general-
izability of this beneﬁcial outcome to all minority
subgroups. The results from this study parallel those
of a related analysis of sex differences (6) and support
the current Class I recommendations from the Amer-
ican College of Cardiology/American Heart Associa-
tion heart failure guidelines, which encourage
screening and implanting all eligible HFrEF patients
regardless of sex, race, or ethnicity.
There are a few limitations to this analysis that
deserve close attention. First, in the subgroup anal-
ysis, even though the relative mortality risk reduction
was similar across all race/ethnicity groups, not all of
these reductions achieved statistical signiﬁcance. For
example, the 95% conﬁdence interval limits around
the point estimate for non-Hispanic blacks in the
ICD/CRT-D cohort straddle the unity line and are
associated with a nonsigniﬁcant p value. Does this
invalidate the study’s conclusions or imply that non-
Hispanic blacks fail to beneﬁt from ICD/CRT-D
therapies? Although different viewpoints may exist
around this interpretation, the short answer is no.
The important construct in examining subgroup
analyses is not to look at individual tests of statistical
signiﬁcance, which are often incorrect and invariably
affected by sample size, but rather to look at the
overall pattern and determine if treatment effect
differed signiﬁcantly between subgroups. In this
study, interaction testing failed to identify any
signiﬁcant differences, which again supports the
generalizability of the results. Second, although
roughly 8,000 patients were included in this analysis,
in some cases, the multivariate Generalized Esti-
mating Equations analysis may have been under-
powered. In the ICD/CRT-D cohort, there was 75%
power to detect a device–race/ethnicity interaction,
but there was only 41% and 15% power in theICD-only and cardiac resynchronization pacemaker/
CRT-D cohorts, respectively. In light of this modest
statistical power, additional well-powered studies
may be needed to conﬁrm the present results. Last,
even though administrative or medical staff were
instructed to record a patient’s self-identiﬁed race/
ethnicity, 44% of study participants had unidentiﬁed
race/ethnicity, a percentage that equals that of the
largest group, non-Hispanic whites, and that may
have confounded the results.
Limitations notwithstanding, this is an important
study. Knowing that there is equal beneﬁt between
racial/ethnic groups only heightens the need to
eliminate disparities in care delivery. The big
question is how best to achieve this. Some potential
solutions include integrating performance improve-
ment programs into clinical practice, leveraging in-
formation technologies to provide clinical decision
support tools, and broadening insurance coverage to
all Americans to improve access to care.
Both general practice performance improvement
programs as well as those speciﬁcally targeting
minority patients have been shown to eliminate
racial/ethnic disparities. For example, participants in
the American Heart Association’s Get With the
Guidelines hospital-based performance improvement
program witnessed signiﬁcant improvement in the
use of ICD therapy for all patients, with the greatest
increase in use occurring in blacks (7). Furthermore,
over a 5-year period, the previously-seen racial dis-
parities in ICD use had been completely eliminated.
Using a similar hospital-based approach, the Robert
Wood Johnson Foundation sponsored a program to
measure and improve care provided to blacks and
Hispanics in select hospitals serving predominantly
minority populations. The quality of cardiac care as
gauged by composite measures improved in 7 of the
10 participating centers, and in 3 hospitals, racial/
ethnic disparities were completely eliminated. The
performance improvement tools utilized in these 2
initiatives provide a framework that other hospitals
can easily adopt to eliminate performance gaps and
elevate the quality of cardiovascular care.
Although the Affordable Care Act has allowed
millions of previously-uninsured Americans to pur-
chase health insurance coverage, it is not yet evident
that insurance reform alone will be sufﬁcient to
eliminate racial/ethnic disparities in ICD/CRT ther-
apy. According to 1 study, the likelihood of receiving
a CRT-D was most closely associated with community
wealth and hospital resources, an association that
persisted even after controlling for insurance status
(8). In the absence of being served by hospitals
capable of maintaining the necessary equipment and
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810skilled practitioners to implant more expensive,
technically-challenging CRT-D devices, patients and
minorities from lower socioeconomic communities
may still be disenfranchised from receiving this form
of life-saving therapy.
For now, the path forward is a little clearer.
Acknowledging that racial/ethnic disparities exist is
an important ﬁrst step, but the time has come to act
on this knowledge. Whether motivated by pay for
performance, public outcomes reporting, or a senseof social justice, providers should now focus on
improving care delivery models to eliminate perfor-
mance gaps and ensure equal care for all Americans.
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